The Food and Drug Administration (FDA) and the American Society of Nephrology, along with other patient and professional organizations, are collaborating to advance scientific understanding of the health and patient safety implications of new and existing medical products. Dr. Roy Chaudhury notes that the goal is to foster the development of therapies for kidney disease by creating a collaborative environment in which the FDA and the greater nephrology community can work together to optimize the evaluation of drugs, devices, and biologics, as well as food products. Listen and learn more about the Kidney Health Initiative goals and objectives.
